Why haven't biologists cured cancer?

Cancer Complexity and Diversity

• Repeated emphasis that there is no single “cure for cancer”; cancers are a large, heterogeneous family of diseases.
• Cancer is framed as rogue self-cells, often a hallmark of aging, exploiting normal body systems and evading immunity.
• Metastasis, genetic instability, and enormous combinatorial space (trillions of cells, billions of base pairs) make prediction and control inherently hard.
• Some cancers are effectively curable; others remain highly resistant, with each patient’s tumor genetically and biologically unique.

Limits of “Find and Destroy the Rogue Cells”

• One camp suggests cancer is solvable by tech that identifies and destroys abnormal cells, largely “ignoring biology.”
• Clinicians and researchers push back: cancer cells often resemble normal cells; the immune system already does imperfect anomaly detection; scale and uncertainty are massive.
• Analogies to debugging an undocumented, non-orthogonal system highlight that interventions can cause severe unintended consequences.

Detection, Diagnostics, and Early Screening

• Strong interest in early detection (e.g., cfDNA, fragmentome, multi-cancer blood tests).
• Others note current assays (e.g., PSA) have poor specificity and that systematically applying sophisticated diagnostics is hard and expensive.
• Some argue early detection could dramatically reduce mortality; others warn that scalability and test quality are major bottlenecks.

Therapies, Approaches, and Reductionism

• Targeted drugs and immunotherapies (e.g., PD-1 inhibitors) cited as genuine breakthroughs, but usually narrow and not universal.
• Debate over whether the dominant gene/protein-centric paradigm is too reductionist; alternative frameworks (e.g., bioelectric/morphogenesis views) are proposed and contested.
• Comparisons with physics underscore how messy, slow, and tool-limited biological experiments are.

Institutions, Incentives, and Culture

• Complaints about regulatory conservatism, especially around clinical trials for terminal patients.
• Concerns about funding scarcity, long timelines, proprietary datasets/instruments, and high “friction” for tests.
• Some blame profit motives and suggest cures are disfavored or buried; others question the plausibility of such schemes.
• Criticism of academic cancer research culture: senior scientists chasing grants and prestige while underpaid juniors do most lab work.
• Broader culture seen as underinvesting in biology and tolerating unhealthy lifestyles, which may counter medical gains.